Effect of high-frequency loading and parathyroid hormone administration on peri-implant bone healing and osseointegration

Abstract

Whole-body vibration and administration of a hormone used to treat osteoporosis can enhance bone healing at the site of a titanium implant. Toru Ogawa of Tohoku University Graduate School of Dentistry in Sendai, Japan, and colleagues gave anti-osteoporosis medications, either parathyroid hormone or the bisphosphonate drug alendronate, to female rat models of osteoporosis. After three weeks of drug administration or a saline control, the researchers inserted titanium implants into the rats’ leg bones. Half the rats were then exposed to whole-body vibration, which applies low-magnitude, high-frequency mechanical forces. A multitude of tests showed that parathyroid hormone improved bone healing at the implant more than alendronate or saline did. The vibrational stimulus further increased the healing. The findings suggest that these treatments could aid in oral bone healing for patients receiving dental implants.

References

[1] Hwang D, Wang HL. Medical contraindications to implant therapy: part I: absolute contraindications. Implant. Dent., 2006, 15: 353-360.

[2] Hwang D, Wang HL. Medical contraindications to implant therapy: part II: relative contraindications. Implant. Dent., 2007, 16: 13-23.

[3] Rubin C, Turner AS, Bain S, Mallinckrodt C, McLeod K. Anabolism. Low mechanical signals strengthen long bones. Nature, 2001, 412: 603-604.

[4] Judex S, Gupta S, Rubin C. Regulation of mechanical signals in bone. Orthod. Craniofac. Res., 2009, 12: 94-104.

[5] Omar H, . Effect of low magnitude and high frequency mechanical stimuli on defects healing in cranial bones. J. Oral. Maxillofac. Surg., 2008, 66: 1104-1111.

[6] Hwang SJ, Lublinsky S, Seo YK, Kim IS, Judex S. Extremely small-magnitude accelerations enhance bone regeneration: a preliminary study. Clin. Orthop. Relat. Res., 2009, 467: 1083-1091.

[7] Sehmisch S, . Effects of low-magnitude, high-frequency mechanical stimulation in the rat osteopenia model. Osteoporos. Int., 2009, 20: 1999-2008.

[8] Shi HF, Cheung WH, Qin L, Leung AH, Leung KS. Low-magnitude high-frequency vibration treatment augments fracture healing in ovariectomy-induced osteoporotic bone. Bone, 2010, 46: 1299-1305.

[9] Russo CR, . High-frequency vibration training increases muscle power in postmenopausal women. Arch. Phys. Med. Rehabil., 2003, 84: 1854-1857.

[10] Rubin C, . Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety. J. Bone Mineral. Res., 2004, 19: 343-351.

[11] Verschueren SM, . Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study. J. Bone Mineral Res., 2004, 19: 352-359.

[12] Iwamoto J, Takeda T, Sato Y, Uzawa M. Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. Aging Clin. Exp. Res., 2005, 17: 157-163.

[13] Gusi N, Raimundo A, Leal A. Low-frequency vibratory exercise reduces the risk of bone fracture more than walking: a randomized controlled trial. BMC Musculoskelet. Disord., 2006, 7

[14] von Stengel S, Kemmler W, Engelke K, Kalender WA. Effects of whole body vibration on bone mineral density and falls: results of the randomized controlled ELVIS study with postmenopausal women. Osteoporos. Int., 2011, 22: 317-325.

[15] Ogawa T, . Influence of whole-body vibration time on peri-implant bone healing: a histomorphometrical animal study. J. Clin. Periodontol., 2011, 38: 180-185.

[16] Ogawa T, . The effect of whole-body vibration on peri-implant bone healing in rats. Clin. Oral. Implants Res., 2011, 22: 302-307.

[17] Zhang X, . Enhancement of implant osseointegration by high-frequency low-magnitude loading. PLoS ONE, 2012, 7: e40488.

[18] Ogawa T, . Stimulation of titanium implant osseointegration through high-frequency vibration loading is enhanced when applied at high acceleration. Calcif. Tissue Int., 2014, 95: 467-475.

[19] Akca K, . Micro-morphologic changes around biophysically stimulated titanium implants in ovariectomized rats. Head Face Med., 2007, 3: 28.

[20] Chen B, Li Y, Xie D, Yang X. Low-magnitude high-frequency loading via whole body vibration enhances bone–implant osseointegration in ovariectomized rats. J. Orthop. Res., 2012, 30: 733-739.

[21] Chatterjee M, . High-frequency loading positively impacts titanium implant osseointegration in impaired bone. Osteoporos. Int., 2015, 26: 281-290.

[22] Neer RM, . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 2001, 344: 1434-1441.

[23] Aspenberg P, . Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J. Bone Mineral. Res., 2010, 25: 404-414.

[24] Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone, 2000, 27: 311-318.

[25] Jiang Y, . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Mineral. Res., 2003, 18: 1932-1941.

[26] Black DM, . The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med., 2003, 349: 1207-1215.

[27] Hodsman AB, . Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev., 2005, 26: 688-703.

[28] Chintamaneni S, Finzel K, Gruber BL. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporos. Int., 2010, 21: 1059-1063.

[29] Skripitz R, Aspenberg P. Parathyroid hormone—a drug for orthopedic surgery?. Acta Orthop. Scand., 2004, 75: 654-662.

[30] Chan HL, McCauley LK. Parathyroid hormone applications in the craniofacial skeleton. J. Dent. Res., 2013, 92: 18-25.

[31] Shirota T, Tashiro M, Ohno K, Yamaguchi A. Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats. J. Oral. Maxillofac. Surg., 2003, 61: 471-480.

[32] Kuchler U, Luvizuto ER, Tangl S, Watzek G, Gruber R. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. J. Dent. Res., 2011, 90: 1001-1006.

[33] Almagro MI, . PTH [1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis. Clin. Oral. Implants Res., 2013, 24: 1027-1034.

[34] Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr. Med. Res. Opin., 2006, 22: 919-928.

[35] Vohra F, Al-Rifaiy MQ, Almas K, Javed F. Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies. Arch. Oral. Biol., 2014, 59: 912-920.

[36] Brown JP, . Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can. Fam. Physician, 2014, 60: 324-333.

[37] Tashjian AH Jr., Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J. Bone Mineral. Res., 2002, 17: 1151-1161.

[38] Vahle JL, . Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol., 2002, 30: 312-321.

[39] Ohtori S, . Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine, 2012, 37: E1464-E1468.

[40] Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J. Oral. Maxillofac. Surg., 2008, 66: 1022-1024.

[41] Fugazzotto PA, Lightfoot WS, Jaffin R, Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J. Periodontol., 2007, 78: 1664-1669.

[42] Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J. Oral. Maxillofac. Surg., 2008, 66: 223-230.

[43] Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int. J. Oral. Maxillofac. Implants, 2006, 21: 349-353.

[44] Zahid TM, Wang BY, Cohen RE. Influence of bisphosphonates on alveolar bone loss around osseointegrated implants. J. Oral. Implantol., 2011, 37: 335-346.

[45] Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner., 1991, 15: 175-191.

[46] Fuchs RK, . Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone, 2007, 41: 290-296.

[47] Campbell GM, Bernhardt R, Scharnweber D, Boyd SK. The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat. Bone, 2011, 49: 225-232.

[48] Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos. Int., 1993, 3: S7-S12.

[49] Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone, 2001, 28: 237-250.